Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

· 2015 · New England Journal of Medicine

Abstract

To the Editor: With regard to the article by Wainwright et al. (July 16 issue),1 randomized trials evaluating the efficacy of lumacaftor, ivacaftor, or both have included only a limited number of patients with a forced expiratory volume in 1 second (FEV1) at baseline of less than 40% of the predicted value. Only 52 patients in the TRAFFIC and TRANSPORT trials and none of the patients in several other studies had this low percentage of predicted FEV1 at baseline. 2,3 Since the majority of patients in resource-limited countries receive a diagnosis of cystic fibrosis later in childhood (when the disease might be advanced), the efficacy of lumacaftor–ivacaftor therapy in patients with poor pulmonary function needs to be evaluated further. Moreover, the current cost of lumacaftor–ivacaftor therapy is almost $300,000 per year; this is much higher than the cost of conventional therapy, which is less than $300 per year. Since the magnitude of change observed with lumacaftor– ivacaftor therapy was “in the range of the magnitudes of change seen in studies of other cystic fibrosis therapeutics,”1 the cost-effectiveness of this form of therapy should be evaluated.4 Finally, in some regions of the world, the Phe508del CFTR mutation is uncommon (e.g., one study5 showed that only 26.9% of patients with cystic fibrosis in the United Arab Emirates are homozygous for this allele). For these patients, conventional therapy (hypertonic saline, azithromycin, or ibuprofen) remains the treatment of choice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc1510466

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 179

Metadata

Venue
New England Journal of Medicine
Published
2015-10-29
Volume
373
Issue
18
Pages
1783-1784
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3140132982
Cited by
179
References
2
FWCI
15.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. https://app.cochat.ai/papers/10.1056/nejmc1510466
The paper
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. (2015). New England Journal of Medicine. https://doi.org/10.1056/nejmc1510466

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.